Fusidic Acid and Insulin-Dependent Diabetes Mellitus

References

• Castaño L., Eisenbarth G. S. Type‐1 diabetes: A chronic autoimmune disease of human, mouse, and rat. Annu. Rev. Immunol 1990; 8: 647–679
   PubMed Web of Science ®Google Scholar
• Bach J. F. Insulin‐dependent diabetes mellitus as an autoimmune disease. Endocr. Rev 1994; 15: 516–542
   PubMed Web of Science ®Google Scholar
• Bottazzo G. F., Dean B. M., McNally J. M., MacKay E. H., Swift G. F., Gamble D. R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med 1985; 313: 353–360
   PubMed Web of Science ®Google Scholar
• Mordes J. P., Desemone J., Rossini A. A. The BB rat. Diabetes. Metab. Rev 1987; 3: 725–750
   PubMed Web of Science ®Google Scholar
• Kolb H., Kolb‐Bachofen V., Roep B. O. Autoimmune versus inflammatory type I diabetes: A controversy?. Immunol. Today 1995; 16: 170–172
   Google Scholar
• Bottazzo G. F., Foulis A. K., Bosi E., Todd I., Pujol‐Borrell R. Pancreatic beta‐cell damage. In search of novel pathogenetic factors. Diabetes Care 1988; 11(SUPPI 1)24–28
   Google Scholar
• Bendtzen K. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic diseases and endocrine diseases. Autoimmunity 1989; 2: 177–189
   PubMed Web of Science ®Google Scholar
• Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: Therapeutic intervention by immunostimulation?. Diabetes 1994; 43: 613–621
   PubMed Web of Science ®Google Scholar
• Corbett J. A., McDaniel M. L. Intraislet release of interleukin 1 inhibits β cell function by inducing p cell expression of inducible nitric oxide synthase. J. Exp. Med 1995; 181: 559–568
   PubMedGoogle Scholar
• Bendtzen K., Mandrup‐Poulsen T., Nerup J., Nielsen J. H., Dinarello C. A., Svenson M. Cytotoxicity of human PI 7 interleukin‐1 for pancreatic islets of Langerhans. Science 1986; 232: 1545–1547
   PubMed Web of Science ®Google Scholar
• Mandrup‐Poulsen T., Helqvist S., Molvig J., Wogensen L. D., Nerup J. Cytokines as immune effector molecules in autoimmune endocrine diseases with special reference to insulin‐dependent diabetes mellitus. Autoimmunity 1989; 4: 191–218
   PubMedGoogle Scholar
• Nicoletti F., Meroni P. L., Barcellini W., Grasso S., Borghi M. O., Lunetta M., et al. FK‐506 prevents diabetes in diabetes‐prone BB/Wor rats. Int. J. Immunopharmacol 1991; 13: 1027–1030
   Google Scholar
• Cavallo M. C., Pozzilli P., Bird C., Wadhwa M., Meager A., Visalli N., et al. Cytokines in sera from insulin‐dependent diabetic patients at diagnosis. Clin. Exp. Immunol 1991; 86: 256–259
   PubMed Web of Science ®Google Scholar
• Nicoletti F., Meroni P. L., Landolfo S., Gariglio M., Guzzardi S., Barcellini W., et al. Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon‐γ. Lancet 1990; 336: 319
   PubMedGoogle Scholar
• Campbell I. L., Kay T. W. H., Oxbrow L., Harrison L. C. Essential role for interferon‐γ and interleukin‐6 in autoimmune insulin‐dependent diabetes in NOD/Wehi mice. J. Clin. Invest 1991; 87: 739–742
   PubMed Web of Science ®Google Scholar
• Debray‐Sachs M., Carnaud C., Boitard C., Cohen H., Gresser I., Bedossa P., et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J. Autoimmun 1991; 4: 237–248
   PubMed Web of Science ®Google Scholar
• Dayer‐Metroz M. D., Duhamel D., Rufer N., Izui S., Carmichaels D., Wollheim C. B., et al. IL‐1 receptor antagonist delays spontaneous autoimmune diabetes in BB rats. Eur. J. Clin. Invest 1992; 22: A50, (Abstract)
   Google Scholar
• Nicoletti R., Di Marco R., Barcellini W., Magro G., Schorlemmer H. U., Kurrle R., et al. Protection from experimental autoimmune diabetes in the non‐obese diabetic mouse with soluble interleukin‐1 receptor. Eur. J. Immunol 1994; 24: 1843–1847
   PubMed Web of Science ®Google Scholar
• Pennline K. J., Roque‐Gaffney E., Monahan M. Recombinant human IL‐10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol 1994; 71: 169–175
   PubMedGoogle Scholar
• Yang X. ‐D., Tisch R., Singer S. M., Cao Z. A., Liblau R. S., Schreiber R. D., et al. Effect of tumor necrosis factor alpha on insulin‐dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J. Exp. Med 1994; 180: 995–1004
   PubMed Web of Science ®Google Scholar
• Sarvetnick N., Shizuru J., Liggitt D., Martin L., McIntyre B., Gregory A., et al. Loss of pancreatic islet tolerance induced by beta‐cell expression of interferon‐gamma. Nature 1990; 346: 844–847
   PubMed Web of Science ®Google Scholar
• Katz J. D., Benoist C., Mathis D. T helper cell subsets in insulin‐dependent diabetes. Science 1995; 268: 1185–1188
   PubMed Web of Science ®Google Scholar
• Corbett J. A., Mikhael A., Shimizu J., Frederick K., Misko T. P., McDaniel M. L., et al. Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine‐sensitive and – resistant stages in the immunological diabetic process. Proc. Nail. Acad. Sci. USA 1993; 90: 8992–8995
   PubMed Web of Science ®Google Scholar
• Eizirik D. L., Sandler S., Welsh N., Cetkovic‐Cvrlje M., Nieman A., Geller D. A., et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J. Clin. Invest 1994; 93: 1968–1974
   PubMed Web of Science ®Google Scholar
• Wu G. Nitric oxide synthesis and the effect of amino‐guanidine and NG‐monomethyl‐L‐arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 1995; 44: 360–364
   PubMed Web of Science ®Google Scholar
• Ziegler A. G., Ziegler R., Vardi P., Jackson R. A., Soeldner J. S., Eisenbarth G. S. Life‐table analysis of progression to diabetes of anti‐insulin autoantibody‐positive relatives of individuals with type I diabetes. Diabetes 1989; 38: 1320–1325
   PubMed Web of Science ®Google Scholar
• Skyler J. S., Marks J. B. Immune intervention in type I diabetes mellitus. Diabetes Review 1993; 1: 15–42
   Google Scholar
• Godtfredsen W. O., Jahnsen S., Lorck H., Roholt K., Tybring L. Fusidic acid: a new antibiotic. Nature 1962; 193: 987
   PubMed Web of Science ®Google Scholar
• von Daehne W., Godtfredsen W. O., Rasmussen P. R. Structure‐activity relationships in fusidic acid‐type antibiotics. Adv. Appl. Microbiol 1979; 25: 95–146
   PubMedGoogle Scholar
• Bellahsene A., Forsgren A. Effect of fusidic acid on the immune response in mice. Infect. Immun 1980; 29: 873–878
   Google Scholar
• Bendtzen K., Diamant M., Faber V. Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. Cytokine 1990; 2: 423–429
   PubMedGoogle Scholar
• Nicoletti F., Di Marco R., Morrone S., Zaccone P., Lembo D., Grasso S., et al. Reduction of spontaneous autoimmune diabetes in diabetes‐prone BB rats with the novel immunosuppressant fusidic acid. Effect on T‐cell proliferation and production of interferon‐gamma. Immunology 1994; 81: 317–321
   Google Scholar
• Nicoletti R., Zaccone P., Di Marco R., Magro G., Grasso S., Morrone S., et al. Effects of sodium fusidate in animal models of insulin‐dependent diabetes mellitus and septic shock. Immunology 1995; 85: 645–650
   Google Scholar
• Chen Y. ‐L., Le Vraux V., Giroud J. ‐P., Chauvelot‐Moachon L. Anti‐tumor necrosis factor properties of non‐peptide drugs in acute‐phase responses. Eur. J. Pharmacol 1994; 271: 319–327
   PubMed Web of Science ®Google Scholar
• Tanaka N., Kinoshita T., Masukawa H. Mechanism of protein synthesis inhibition by fusidic acid and related antibiotics. Biochem. Biophys. Res. Commun 1968; 30: 278–283
   Google Scholar
• Reeves D. S. The pharmacokinetics of fusidic acid. J. Antimicrob. Chemother 1987; 20: 467–476
   PubMed Web of Science ®Google Scholar
• Nicoletti F., Meroni P. L., Lunetta M., Vigo R., Palermo T., Papalia D., et al. Sodium fusidate and increased remission rate of insulin‐dependent diabetes mellitus. Lancet 1991; 337: 1292
   Google Scholar
• Buschard K., Pedersen C., Hansen S. V., Hageman I., Aaen K., Bendtzen K. Anti‐diabetogenic effect of fusidic acid in diabetes prone BB rats. Autoimmunity 1992; 14: 101–104
   Web of Science ®Google Scholar
• Bendtzen K., Diamant M., Horn T., Pedersen C., Buschard K. Effect of fusidic acid on interleukin‐1 (IL‐1)‐ and IL‐6‐induced pancreatic p‐cell functions in rats. J. Endocrinol 1992; 132: 345–352
   Google Scholar
• Burkart V., Bellmann K., Hartmann B., Heller B., Imai Y., Kolb H. Fusidic acid suppresses nitric oxide toxicity in pancreatic islet cells. Biochem. Pharmacol 1994; 48: 1379–1385
   PubMed Web of Science ®Google Scholar
• Horn T., Bendtzen K., Hageman I., Buschard K. Morphological effects of sodium fusidate (fusidin) on pancreatic islet cells: An electron microscopic study. Pharmacol. Toxicol 1994; 75: 228–230
   Google Scholar
• Famularo G., De Simone C., Tzantzoglou S., Trinchieri V., Moretti S., Tonietti G. In viva and in vitro efficacy of fusidic acid in HIV infection. Ann. N. Y. Acad. Sci 1993; 685: 341–343
   Google Scholar
• Bendtzen K., Vesti‐Nielsen N., Petersen J., Andersen V., Bendixen G. Treatment of chronic endogenous uveitis with fusidic acid. Lancet 1991; 337: 552–553
   PubMed Web of Science ®Google Scholar
• Langholz E., Brynskov J., Bendtzen K., Vilien M., Binder V. Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. Aliment. Pharmacol. Thier 1992; 6: 495–502
   Google Scholar
• Findon G., Miller T. E., Rowe L. C. Pharmacokinetics of fusidic acid in laboratory animals. Lab. Anim. Sci 1991; 41: 462–465
   Google Scholar